January 6, 2022SHILAP Revista de lepidopterología64 citationsOpen Access
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee
Structured PICO
What is the adjudicated rate of arterial occlusive events associated with ponatinib in the PACE trial?
P
Population
Patients in the PACE trial
I
Intervention
Ponatinib
O
Outcome
Arterial occlusive events (AOE)safety
Independent adjudication suggests the risk of arterial occlusive events with ponatinib in the PACE trial was previously overestimated.
Abstract
This independent adjudication study identified lower AOE rates than previously reported, suggesting earlier overestimation that may inaccurately reflect AOE risk with ponatinib. This trial was registered under ClinicalTrials.gov identifier NCT01207440 on September 23, 2010 ( https://clinicaltrials.gov/ct2/show/NCT01207440 ).